Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement.
Overview
Choosing between Abbott Laboratories (NYSE:ABT) and Johnson & Johnson (NYSE:JNJ) involves weighing steady growth against massive scale. Both healthcare giants offer stability, but which represents the superior investment for you in 2026?
Abbott focuses on high-tech diagnostics and life-saving medical devices, while Johnson & Johnson operates as a pharmaceutical powerhouse with a growing medtech division. Investors often compare them because they are cornerstones of the healthcare sector, providing consistent dividends and exposure to global demographic trends such as aging populations.
Details
Abbott is a healthcare leader providing diagnostics, nutrition, and cardiovascular tools to a global audience. Its March 2026 acquisition of Exact Sciences added advanced cancer diagnostics to its portfolio. Management notes that no single customer loss would materially hurt the business. This diversified approach makes it a staple among medical device stocks for many portfolios.
Source
Originally published at www.fool.com.